Regeneron EPS beat by $3.82 and revenue beat by $540M.
Context
What happened: Regeneron Pharmaceuticals (REGN) reported Q3 Non-GAAP EPS of $20.07 and revenue of $5.1B, both beating estimates.
Key numbers: Non-GAAP EPS $20.07, beat by $3.82. Revenue $5.1B, up 36.0% Y/Y, beat by $540M. The company also provided full year 2026 financial guidance.
Why it matters: Both EPS and revenue came in above consensus estimates, and the company issued full year 2026 financial guidance.
Coverage: 4 outlets in 24h